FI115443B - Förfarande för framställning av orala sammansättningar av ett antimykotikum - Google Patents
Förfarande för framställning av orala sammansättningar av ett antimykotikum Download PDFInfo
- Publication number
- FI115443B FI115443B FI961436A FI961436A FI115443B FI 115443 B FI115443 B FI 115443B FI 961436 A FI961436 A FI 961436A FI 961436 A FI961436 A FI 961436A FI 115443 B FI115443 B FI 115443B
- Authority
- FI
- Finland
- Prior art keywords
- composition
- cyclodextrin
- process according
- itraconazole
- propylene glycol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Claims (7)
1. Förfarande för framställning av en oralt admi-nistrerbar, terapeutiskt användbar, vattenhaltig komposi-5 tion, vilken komposition innehäller: (a) itrakonazol eller saperkonazol, (b) en tillräcklig mängd cyklodextrin eller ett derivat därav för att fungera som lösningsmedel för itrakonazol eller saperkonazol, 10 (c) ett surt vattenmedium som flytande bulkbärare, (d) alkoholmedlösningsmedel som har valts frän gruppen etanol, propylenglykol och glycerol, (e) tillräckliga mängder av ett eller flera farma-ceutiskt godtagbara intensivsötningsmedel och ett eller 15 flera bulksötningsmedel, (f) en tillräcklig mängd av ett eller flera farma-ceutiskt godtagbara aromämnen för att maskera den vatten-haltiga lösningens smak, kännetecknat av att det omfattar steg, i 20 vilka: (i) ett aktivt ämne upplöses i alkoholmedlösnings-: medlet och en syra, *; (ii) cyklodextrin upplöses i vatten och i denna j. lösning tillsättes den i punkt (i) framställda lösningen 25 under samtidig omröring tili en homogen blandning, ♦ · (iii) sötningsmedlet (-medlen) och aromämnet !!! (-ämnena) tillsättes.
' 2. Förfarande enligt patentkrav 1, känneteck nat av att man framställer en komposition, i vilken cyk- • « · : 30 lodextrin är hydroxipropyl- β-cyklodextrin, vars MS-värde II» är i omrädet 0,35 - 3 och som innehäller under 5 % icke- : substituerat β-cyklodextrin. t » · t···,
3. Förfarande enligt patentkrav 1, känneteck- » · nat av att man framställer en komposition, i vilken al-; i 35 koholmedlösningsmedlet är propylenglykol. 115443
4. Förfarande enligt patentkrav 1, känneteck-n a t av att man framställer en komposition, vars pH-värde är 2,0 ± 0,1.
5. Förfarande enligt patentkrav 1, känneteck-5 nat av att intensivsötningsmedlet väljs frän gruppen sackarin, natrium- eller kalciumsackarin och bulksötnings-medlet väljs frän gruppen sorbitol, mannitol, fruktos, sackaros, maltos, glukos, karamell eller honung.
6. Förfarande enligt patentkrav 1, känneteck-10 nat av att man framställer en komposition som omfattar som vikt- eller volymprocent beräknat pä kompositionens totalvolym (a) 4 vikt/volym-% itrakonazol, (b) 60 vikt/volym-% hydroxipropyl-p-cyklodextrin, 15 (c) 10 volym/volym-% propylenglykol, (d) syra och bas för regiering av komposit ionens pH-värde tili intervallet 2,0 ± 0,1, (e) 0,08 vikt/volym-% natriumsackarin, (f) upp till 1 vikt/volym-% av ett eller flera 20 aromämnen och (g) vatten.
>* 7. Förfarande enligt patentkrav 1, känneteck- .* n a t av att man framställer en komposition som omfattar g’ som vikt- eller volymprocent beräknat pä kompositionens 25 totalvolym ; (a) 1 vikt/volym-% itrakonazol eller saperkonazol, (b) 40 vikt/volym-% hydroxipropyl^-cyklodextrin, (c) 10 volym/volym-% propylenglykol, : ,·, (d) syra och bas för regiering av kompositionens / 30 pH-värde tili intervallet 2,0 ± 0,1, » I (e) 0,06 vikt/volym-% natriumsackarin, » · i (f) 19 volym/volym-% av icke-kristalliserande lös- : : ning av sorbitol (70 %), 115443 (g) upp till 1 vikt/volym-% av ett eller flera aromämnen, (h) 0,02 vikt/volym-% karamellsötningsmedel och (i) vatten. » · t 1 t t 1 • · ♦ » · • · I ( I > * « t »
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12950493A | 1993-09-30 | 1993-09-30 | |
| US12950493 | 1993-09-30 | ||
| EP9403169 | 1994-09-22 | ||
| PCT/EP1994/003169 WO1995008993A1 (en) | 1993-09-30 | 1994-09-22 | Oral formulations of an antifungal |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI961436A FI961436A (sv) | 1996-03-29 |
| FI961436A0 FI961436A0 (sv) | 1996-03-29 |
| FI115443B true FI115443B (sv) | 2005-05-13 |
Family
ID=22440301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI961436A FI115443B (sv) | 1993-09-30 | 1996-03-29 | Förfarande för framställning av orala sammansättningar av ett antimykotikum |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US5707975A (sv) |
| EP (1) | EP0721337B1 (sv) |
| JP (1) | JP3034048B2 (sv) |
| CN (1) | CN1086579C (sv) |
| AP (1) | AP630A (sv) |
| AT (1) | ATE209916T1 (sv) |
| AU (1) | AU692180B2 (sv) |
| CA (1) | CA2170622C (sv) |
| CY (1) | CY2272B1 (sv) |
| CZ (1) | CZ288026B6 (sv) |
| DE (1) | DE69429359T2 (sv) |
| DK (1) | DK0721337T3 (sv) |
| ES (1) | ES2169087T3 (sv) |
| FI (1) | FI115443B (sv) |
| HK (1) | HK1010689A1 (sv) |
| HU (1) | HU221632B1 (sv) |
| IL (1) | IL111093A (sv) |
| MY (1) | MY111136A (sv) |
| NO (1) | NO308985B1 (sv) |
| NZ (1) | NZ273619A (sv) |
| OA (1) | OA10276A (sv) |
| PH (1) | PH31594A (sv) |
| PL (1) | PL313731A1 (sv) |
| PT (1) | PT721337E (sv) |
| RO (1) | RO115114B1 (sv) |
| RU (1) | RU2118899C1 (sv) |
| SG (1) | SG48826A1 (sv) |
| SK (1) | SK282627B6 (sv) |
| TW (1) | TW349870B (sv) |
| WO (1) | WO1995008993A1 (sv) |
| ZA (1) | ZA947619B (sv) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2243994T5 (es) | 1996-04-19 | 2009-10-29 | Grifols Inc. | Procedimiento para la inactivacion virica de proteinas de la sangre liofilizadas. |
| KR20060066753A (ko) * | 1997-10-22 | 2006-06-16 | 젠스 포니카우 | 진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도 |
| US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| CA2362728C (en) | 1999-03-24 | 2009-06-23 | Fmc Corporation | Improved aqueous solubility pharmaceutical formulations |
| ATE313319T1 (de) | 1999-03-31 | 2006-01-15 | Janssen Pharmaceutica Nv | Vorgelatinierte stärke in einer formulierung mit gesteuerter freigabe |
| AU5975700A (en) * | 1999-07-02 | 2001-01-22 | Janssen Pharmaceutica N.V. | Nasal formulation of an antifungal |
| CA2291346A1 (en) | 1999-11-26 | 2001-05-26 | Bernard Charles Sherman | Antifungal solutions |
| US6673373B2 (en) | 2001-02-01 | 2004-01-06 | Carlsbad Technology Inc. | Antifungal formulation and the methods for manufacturing and using the same |
| EP1372662A1 (en) * | 2001-03-05 | 2004-01-02 | Ortho-Mcneil Pharmaceutical, Inc. | Taste masked liquid pharmaceutical compositions |
| CA2363376A1 (en) * | 2001-11-16 | 2003-05-16 | Bernard Charles Sherman | Solid pharmaceutical compositions for oral administration comprising itraconazole |
| US7446107B2 (en) * | 2002-02-15 | 2008-11-04 | Transform Pharmaceuticals, Inc. | Crystalline forms of conazoles and methods of making and using the same |
| US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| WO2003074474A2 (en) * | 2002-03-01 | 2003-09-12 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
| EP1511490A4 (en) * | 2002-05-31 | 2009-03-11 | Transform Pharmaceuticals Inc | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS |
| US20070059356A1 (en) * | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| CA2489984A1 (en) * | 2002-06-21 | 2003-12-31 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
| WO2007014130A2 (en) * | 2005-07-21 | 2007-02-01 | Nomir Medical Technologies, Inc. | Near infrared microbial elimination laser system (nimels) |
| CN1255105C (zh) * | 2002-12-17 | 2006-05-10 | 上海医药工业研究院 | 齐拉西酮及其盐的水溶性包合物及其制备方法 |
| US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
| CA2440172C (en) * | 2003-09-05 | 2011-01-11 | Bernard Charles Sherman | Itraconazole solution |
| US20050074494A1 (en) * | 2003-10-06 | 2005-04-07 | Xiu-Xiu Cheng | Itraconazole immediate release formulation |
| US20050118265A1 (en) * | 2003-11-28 | 2005-06-02 | Anandi Krishnan | Antifungal oral dosage forms and the methods for preparation |
| EP1691801A4 (en) * | 2003-12-08 | 2009-12-09 | Univ Arizona State | SYNERGISTIC ANTICANCER COMPOSITIONS |
| GR1005154B (el) | 2005-02-09 | 2006-03-13 | Verisfield (Uk) Ltd. | Σταθερες φαρμακευτικες συνθεσεις ιτρακοναζολης σευδατικο περιβαλλον |
| WO2007047253A2 (en) * | 2005-10-11 | 2007-04-26 | Eastman Chemical Company | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| CL2007002026A1 (es) * | 2006-07-13 | 2008-06-06 | Los Angeles Biomed Res Inst | Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica. |
| CA2658521C (en) | 2006-12-04 | 2015-06-09 | Supernus Pharmaceuticals, Inc. | Enhanced immediate release formulations of topiramate |
| EP2257160B1 (en) | 2008-02-21 | 2017-07-05 | Sequoia Pharmaceuticals, Inc. | Diamide inhibitors of cytochrome p450 |
| US20100009009A1 (en) | 2008-07-10 | 2010-01-14 | Micropure, Inc. | Method and composition for prevention and treatment of oral fungal infections |
| US20100233101A1 (en) | 2009-02-13 | 2010-09-16 | Micropure, Inc. | Composition and method for the oxidative consumption of salivary biomolecules |
| US20120093828A1 (en) | 2009-03-19 | 2012-04-19 | Ibrahim Ashraf S | Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases |
| CA2821823C (en) * | 2010-12-16 | 2019-05-07 | Board Of Regents, The University Of Texas System | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
| CN102670490A (zh) * | 2012-05-10 | 2012-09-19 | 南京特丰药业股份有限公司 | 一种伊曲康唑口服溶液及其制备方法 |
| CN103230363A (zh) * | 2013-03-29 | 2013-08-07 | 湖北凤凰白云山药业有限公司 | 一种抗真菌的口服溶液 |
| CA3020197A1 (en) | 2017-09-01 | 2019-03-01 | Micropure, Inc. | Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions |
| RU2707286C1 (ru) * | 2019-07-02 | 2019-11-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | Фармацевтическая противогрибковая композиция на основе производного хлорфенилбутандиона и способ её получения |
| CN114191386B (zh) * | 2021-12-26 | 2024-03-12 | 苏州海景医药科技有限公司 | 一种波生坦口服溶液的制备方法 |
| CN114191387A (zh) * | 2021-12-26 | 2022-03-18 | 苏州海景医药科技有限公司 | 一种伏立康唑口服液的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459731A (en) * | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US4267179A (en) * | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
| US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US4863737A (en) * | 1985-05-01 | 1989-09-05 | University Of Utah | Compositions and methods of manufacture of compressed powder medicaments |
| US4883785A (en) * | 1984-07-27 | 1989-11-28 | Chow Wing Sun | Complex of anti-fungal agent and cyclodextrin and method |
| US4870060A (en) * | 1985-03-15 | 1989-09-26 | Janssen Pharmaceutica | Derivatives of γ-cylodextrin |
| GB8506792D0 (en) * | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
| US4916134A (en) * | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| AU609242B2 (en) * | 1988-01-29 | 1991-04-26 | Novartis Ag | Cyclosporin compositions |
| ES2158859T3 (es) * | 1992-03-18 | 2001-09-16 | Janssen Pharmaceutica Nv | Estereoisomeros itraconazol y saperconazol. |
-
1994
- 1994-09-08 PH PH48937A patent/PH31594A/en unknown
- 1994-09-08 TW TW083108274A patent/TW349870B/zh not_active IP Right Cessation
- 1994-09-22 EP EP94927639A patent/EP0721337B1/en not_active Expired - Lifetime
- 1994-09-22 PL PL94313731A patent/PL313731A1/xx unknown
- 1994-09-22 RU RU96108776A patent/RU2118899C1/ru active
- 1994-09-22 AU AU76979/94A patent/AU692180B2/en not_active Expired
- 1994-09-22 CA CA002170622A patent/CA2170622C/en not_active Expired - Lifetime
- 1994-09-22 DE DE69429359T patent/DE69429359T2/de not_active Expired - Lifetime
- 1994-09-22 DK DK94927639T patent/DK0721337T3/da active
- 1994-09-22 RO RO96-00673A patent/RO115114B1/ro unknown
- 1994-09-22 ES ES94927639T patent/ES2169087T3/es not_active Expired - Lifetime
- 1994-09-22 SG SG1996002179A patent/SG48826A1/en unknown
- 1994-09-22 CZ CZ1996823A patent/CZ288026B6/cs not_active IP Right Cessation
- 1994-09-22 AP APAP/P/1996/000792A patent/AP630A/en active
- 1994-09-22 WO PCT/EP1994/003169 patent/WO1995008993A1/en active IP Right Grant
- 1994-09-22 JP JP7510099A patent/JP3034048B2/ja not_active Expired - Lifetime
- 1994-09-22 SK SK399-96A patent/SK282627B6/sk not_active IP Right Cessation
- 1994-09-22 US US08/604,950 patent/US5707975A/en not_active Expired - Lifetime
- 1994-09-22 HU HU9600804A patent/HU221632B1/hu unknown
- 1994-09-22 NZ NZ273619A patent/NZ273619A/en not_active IP Right Cessation
- 1994-09-22 CN CN94193602A patent/CN1086579C/zh not_active Expired - Lifetime
- 1994-09-22 PT PT94927639T patent/PT721337E/pt unknown
- 1994-09-22 AT AT94927639T patent/ATE209916T1/de active
- 1994-09-28 MY MYPI94002583A patent/MY111136A/en unknown
- 1994-09-29 IL IL11109394A patent/IL111093A/en not_active IP Right Cessation
- 1994-09-29 ZA ZA947619A patent/ZA947619B/xx unknown
-
1996
- 1996-03-27 NO NO961233A patent/NO308985B1/no not_active IP Right Cessation
- 1996-03-29 OA OA60806A patent/OA10276A/en unknown
- 1996-03-29 FI FI961436A patent/FI115443B/sv not_active IP Right Cessation
-
1998
- 1998-10-27 HK HK98111559A patent/HK1010689A1/xx not_active IP Right Cessation
-
2002
- 2002-05-15 CY CY0200025A patent/CY2272B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI115443B (sv) | Förfarande för framställning av orala sammansättningar av ett antimykotikum | |
| DK175288B1 (da) | Farmaceutiske midler indeholdende lægemidler, der er ustabile eller sparsomt oplöselige i vand, og fremgangsmåder til deres fremstilling | |
| US6407079B1 (en) | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation | |
| EP0900088B1 (en) | Inclusion complexes of aryl-heterocyclic salts | |
| EP0759741B1 (en) | Mucoadhesive emulsions containing cyclodextrin | |
| FI84076B (fi) | Nya derivat av -cyklodextrin och deras framstaellning. | |
| US6699849B1 (en) | Cyclodextrin complexes of benzodiazepines | |
| US20060193783A1 (en) | Low dose corticosteroid composition | |
| US6077871A (en) | Droloxifene pharmaceutical compositions | |
| WO2001001955A1 (en) | Nasal formulation of an antifungal | |
| US20190183891A1 (en) | Voriconazole inclusion complexes | |
| CN114191387A (zh) | 一种伏立康唑口服液的制备方法 | |
| FI86507C (sv) | Förfarande för framställnig av terapeutiska kompositioner innehållande -cyklodextrinderivat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 115443 Country of ref document: FI |
|
| MA | Patent expired |